The National Institute on Aging awarded a five-year, $1.4 million grant to the UArizona Center for Innovation in Brain Science for Translational Research in Alzheimer’s Disease and Related Dementias, a predoctoral training program that addresses the need for highly trained Alzheimer’s disease researchers.

Neuromodulation company StimAire, which collaborated with researchers at the College of Medicine – Tucson, has concluded the first-in-human study of an injectable stimulator for obstructive sleep apnea in Australia.

Researchers at the Center for Innovation in Brain Science received a $1.4 million Translational Research in Alzheimer’s Disease and Related Dementias grant.

“Untangled Shadows,” part of the UArizona Health Sciences’ El Mirador Project collection, is a digital installation blending light, motion and nature.

Howard D. Silverman, MD, professor in the Department of Biomedical Informatics at the College of Medicine – Phoenix, is quoted in an explainer on medical specialties, including biomedical informatics, which involves collecting and analyzing patients’ health information and applying those insights to improve health.

Physician shortages are affecting many rural communities, sparking more than 40 medical schools to create rural training tracks.

A startup has developed an artificial intelligence algorithm that it says can analyze results from an eye scanner and detect signs of Alzheimer’s 20 years before symptoms develop. The tool is part of broader work by startups and researchers to harness AI to unlock the mysteries of the disease.

Medical office buildings remain in high demand in a weak real estate market. The story cites the August sale of Banner – University North Campus, which encompasses the UArizona Cancer Center, for $134 million.

Media and health agencies are reporting a noticeable increase in child poisoning cases associated with THC edibles. The Arizona Poison and Drug Information Center at the R. Ken Coit College of Pharmacy reports a decrease in THC-related calls but underscored the persistence of incidents involving edibles.

The Drug Enforcement Agency received a recommendation to reclassify cannabis as a Schedule III drug, a move that would be a boon to research and patient care.